In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus

Human Gene Therapy

Volumn 23, Issue 2, 2012, Pages 218-230

  Adamson, R E ^a   Frazier, A A ^b   Evans, H ^a   Chambers, K F ^a   Schenk, E ^c   Essand, M ^d   Birnie, R ^b   Mitry, R R ^e   Dhawan, A ^e   Maitland, N J ^a,b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Pro Cure Therapeutics Ltd   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UPPSALA UNIVERSITY   (Sweden)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GREEN FLUORESCENT PROTEIN; ONCOLYTIC ADENOVIRUS; VIRUS PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL TYPE; CELL VIABILITY; CYTOPLASM; CYTOTOXICITY; DIGITAL IMAGING; EPITHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LIVER CELL; MALE; NONHUMAN; PROSTATE CELL; UMBILICAL VEIN ENDOTHELIAL CELL; UROTHELIUM CELL; VIRUS GENOME; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ANIMALS; CELL LINE, TUMOR; COXSACKIE AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; ENDOTHELIAL CELLS; EPITHELIAL CELLS; GENE EXPRESSION; GENETIC VECTORS; HEPATOCYTES; HUMANS; MALE; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; ORGAN SPECIFICITY; PRIMARY CELL CULTURE; PROSTATIC NEOPLASMS; VIRAL PROTEINS; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 84856819647     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.021     Document Type: Article

References (25)

1. Au, T., Thorne, S., Korn, W.M., et al. (2007). Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther. 14, 139-150. (Pubitemid 46106958)
2. Carlisle, R.C., Di, Y., Cerny, A.M., et al. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 13, 1909-1918.
3. Carlsson, B., Cheng, W.S., Tötterman, T.H., and Essand M. (2003). Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. Br. J. Haematol. 121, 428-438. (Pubitemid 36628334)
4. Carmen, I.H. (2001). A death in the laboratory: the politics of the Gelsinger aftermath. Mol. Ther. 3, 425-428. (Pubitemid 32509834)
5. Cawood, R., Wong, S.-L., Di, Y., et al. (2011). MicroRNA controlled adenovirus mediates anti-cancer efficacy without affecting endogenous microRNA activity. PLoS One 6, e16152.
6. Cheng, W.S., Giandomenico, V., Pastan, I., and Essand, M. (2003). Characterization of the androgen-regulated prostatespecific T cell receptor c-chain alternate reading frame protein (TARP) promoter. Endocrinology. 144, 3433-3440. (Pubitemid 36904419)
7. Cheng, W.S., Kraaij, R., Nilsson, B., et al. (2004). A novel TARPpromoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol. Ther. 10, 355-364. (Pubitemid 39117880)
8. Cheng, W.S., Dzojic, H., Nilsson, B., et al. (2006). An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer. Cancer Gene Ther. 13, 13-20. (Pubitemid 41816345)
9. DeWeese, T.L., van der Poel, H., Li, S., et al. (2001). A phase I clinical trial of CV706, a replications-competent, PSA selective oncolytic adenovirus for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61, 7464-7472. (Pubitemid 32995035)
10. Djavan, B., Judd, M.W., Zlotta, A., et al. (2003). PSA progression following radical prostatectomy and radiation therapy: new standards in the new millenium. Eur. Urol. 43, 12-27. (Pubitemid 36134310)
11. Freytag, S.O., Rogulski, K.R., Paielli, D.L., et al. (1998). A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9, 1323-1333. (Pubitemid 28312897)
12. Freytag, S.O., Khil, M., Stricker, H., et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62, 4968-4976. (Pubitemid 34984421)
13. Freytag, S.O., Stricker, H., Pegg, J., et al. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose threedimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res. 63, 7497-7506. (Pubitemid 37413494)
14. He, T.-C., Zhou, S., da Costa, L.T., et al. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95, 2509-2514. (Pubitemid 28145972)
15. Jogler, C., Hoffman, D., Theegarten, D., et al. (2006). Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J. Virol. 80, 3549-3558.
16. Kim, J.H., Kim, S.H., Brown, S.L., and Freytag, S.O. (1994). Selective enhancement by an antiviral agent of the radiationinduced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res. 54, 6053-6056. (Pubitemid 24378627)
17. Maitland, N., Chamber, K., Georgopoulos, L., et al.; GIANT FP6 Consortium. (2010). Gene transfer vectors targeted to human prostate cancer: do we need better preclinical testing systems? Hum. Gene Ther. 21, 815-827.
18. Mitry, R.R., Sarraf, C.E., Havĺk, R., and Habib, N.A. (2000). Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment. Hepatology. 31, 885-889. (Pubitemid 30169935)
19. Nemunaitis, J., Cunningham, C., Buchanan, A., et al. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8, 746-759. (Pubitemid 32509788)
20. Rogulski, K.R., Freytag, S.O., Zhang, K., et al. (2000). In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60, 1193-1196. (Pubitemid 30151981)
21. Sakurai, F., Katayama, K., and Mizuguchi, H. (2011). Micro-RNA-regulated transgene expression systems for gene therapy and virotherapy. Front. Biosci. 17, 2389-2401.
22. Schenk, E., Essand, M., Bangma, C.H., et al. (2010) Clinical adenoviral gene therapy for prostate cancer. Hum. Gene Ther. 21, 807-813.
23. Small, E.J., Carducci, M.A., Burke, J.M., et al. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostatespecific antigen targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 14, 107-117. (Pubitemid 43899483)
24. Tokuyasu, K.T. (1986). Cryosection for immunochemistry. J. Electron Microsc. (Tokyo) 35, 1977-1978.
25. Vorberg, S.A., and Hunt, K.K. (2002). Production of adenoviral gene therapy. Oncologist. 7, 46-59.